Table 1.
Major Preexposure Prophylaxis Trials
| Study | Efficacy | Estimated Adherence by Drug Concentration |
|---|---|---|
| PP-TDF/FTC [10] | 75% | 75%–80% |
| PP-TDF [10] | 67% | 67%–80% |
| TDF2 –TDF/FTC [14] | 62% | 80% |
| BKK-TDF [11] | 49% | 67% |
| iPrEX –TDF/FTC [12] | 44% | 51% |
| CAPRISA–TDF Gel BAT24 [9] | 39% | 38%–98% |
| VOICE-TDF Gel Daily [13] | 14.7% | 22% |
| FemPrEP–TDF/FTC [15] | 6% | 37% |
| VOICE-TDF/FTC [13] | −4% | 29% |
| VOICE-TDF [13] | −49% | 28% |
Abbreviations: BKK, Bangkok Tenofovir Study; CAPRISA, Centre for the AIDS Programme of Research in South Africa; FTC, Emtricitabine; iPrEx, Iniciativa Profilaxis Pre-Exposición; PP, Partners PrEP; TDF, Tenofovir disoproxil fumarate; TDF2, Botswana TDF/FTC Oral HIV Prophylaxis Trial; VOICE, Vaginal and Oral Interventions to Control the Epidemic.